<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="epub">1935-2735</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">10-PNTD-RA-1485R2</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0000916</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Infectious Diseases/Neglected Tropical Diseases</subject><subject>Infectious Diseases/Protozoal Infections</subject><subject>Public Health and Epidemiology/Health Services Research and Economics</subject><subject>Public Health and Epidemiology/Immunization</subject></subj-group></article-categories><title-group><article-title>The Potential Economic Value of a <italic>Trypanosoma cruzi</italic> (Chagas Disease) Vaccine in Latin America</article-title><alt-title alt-title-type="running-head">Economics Chagas Disease Vaccine</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>Bruce Y.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bacon</surname><given-names>Kristina M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Connor</surname><given-names>Diana L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Willig</surname><given-names>Alyssa M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bailey</surname><given-names>Rachel R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Public Health Computational and Operations Research (PHICOR), School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Galvani</surname><given-names>Alison P.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">Yale University, United States of America</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">BYL1@pitt.edu</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: BYL KMB RRB. Performed the experiments: KMB DLC AMW. Analyzed the data: BYL KMB DLC AMW RRB. Contributed reagents/materials/analysis tools: BYL RRB. Wrote the paper: BYL KMB DLC.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2010</year></pub-date><volume>4</volume><issue>12</issue><elocation-id>e916</elocation-id><history>
<date date-type="received"><day>20</day><month>8</month><year>2010</year></date>
<date date-type="accepted"><day>15</day><month>11</month><year>2010</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><copyright-holder>Lee et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec>
<title>Background</title>
<p>Chagas disease, caused by the parasite <italic>Trypanosoma cruzi (T. cruzi)</italic>, is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccine against <italic>T. cruzi</italic>.</p>
</sec><sec>
<title>Methodology/Principal Findings</title>
<p>We constructed a decision analytic Markov computer simulation model to assess the potential economic value of a <italic>T. cruzi</italic> vaccine in Latin America from the societal perspective. Each simulation run calculated the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination. Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50–$200), vaccine efficacy (range: 25%–75%), the cost of acute-phase drug treatment (range: $10–$150 to account for variations in acute-phase treatment regimens), and risk of infection (range: 1%–20%). Additional analyses determined the incremental cost of vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-effective when the ICER was ≤1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the GDP/capita, and not cost-effective when the ICER was &gt;3 times the GDP/capita. Our results showed vaccination to be very cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase.</p>
</sec><sec>
<title>Conclusions/Significance</title>
<p>Results indicate that a <italic>T. cruzi</italic> vaccine could provide substantial economic benefit, depending on the cost of the vaccine, and support continued efforts to develop a human vaccine.</p>
</sec></abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>The substantial burden of Chagas disease, especially in Latin America, and the limitations of currently available treatment and control strategies have motivated the development of a <italic>Trypanosoma cruzi</italic> (<italic>T. cruzi</italic>) vaccine. Evaluating a vaccine's potential economic value early in its development can answer important questions while the vaccine's key characteristics (e.g., vaccine efficacy targets, price points, and target population) can still be altered. This can assist vaccine scientists, manufacturers, policy makers, and other decision makers in the development and implementation of the vaccine. We developed a computational economic model to determine the cost-effectiveness of introducing a <italic>T. cruzi</italic> vaccine in Latin America. Our results showed vaccination to be very cost-effective, in many cases providing both cost savings and health benefits, even at low infection risk and vaccine efficacy. Moreover, our study suggests that a vaccine may actually “pay for itself”, as even a relatively higher priced vaccine will generate net cost savings for a purchaser (e.g., a country's ministry of health). These findings support continued investments in and efforts toward the development of a human <italic>T. cruzi</italic> vaccine.</p>
</abstract><funding-group><funding-statement>This study was supported by the Vaccine Modeling Iniative (VMI), funded by the Bill and Melinda Gates Foundation and the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Chagas disease (American trypanosomiasis), caused by the parasite <italic>Trypanosoma cruzi (T. cruzi)</italic>, is a leading etiology of non-ischemic heart disease worldwide <xref ref-type="bibr" rid="pntd.0000916-SosaEstani1">[1]</xref> and has a substantial impact on Latin America, resulting in an estimated 750,000 productive life years lost and 1.2 billion dollars lost annually <xref ref-type="bibr" rid="pntd.0000916-CubillosGarzon1">[2]</xref>, <xref ref-type="bibr" rid="pntd.0000916-MarinNeto1">[3]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Wanderley1">[4]</xref>. Chagas disease has three established phases: acute, indeterminate, and chronic. While acute disease is primarily asymptomatic, cases often transition to the chronic phase and clinically manifest as cardiomyopathy and subsequent congestive heart failure (CHF) decades after infection <xref ref-type="bibr" rid="pntd.0000916-SosaEstani1">[1]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref>. Furthermore, those who develop Chagas-related CHF have poorer prognoses and higher mortality rates than those with other CHF etiologies <xref ref-type="bibr" rid="pntd.0000916-CubillosGarzon1">[2]</xref>.</p>
<p>The substantial burden of Chagas disease and the limitations of current interventions have motivated efforts to develop a vaccine against <italic>T. cruzi</italic>. Although currently available drugs (benznidazole and nifurtimox) are moderately efficacious when administered during the acute phase, they have been minimally successful in treating chronic infection <xref ref-type="bibr" rid="pntd.0000916-Urbina1">[7]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Coura1">[8]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Cancado1">[9]</xref>. Low rates of symptomatic acute illness limit the utilization (and thus, the benefit) of these drugs <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Coura1">[8]</xref>. The lack of an available vaccine has left insecticide spraying for T. <italic>cruzi</italic> vectors (reduvidae insects) as the primary control strategy. However, implementing successful mass spraying can be challenging <xref ref-type="bibr" rid="pntd.0000916-Guhl1">[10]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Tarleton1">[11]</xref>. Mass spraying requires both repeated and consistent reapplication, which in turn necessitates funding, personnel, and equipment. Due to a lack of national-level funding, local communities may not have the resources to maintain spraying. Furthermore, increased use of insecticides has elicited resistance among vectors in Argentina and Bolivia and may lead to untoward health effects for humans <xref ref-type="bibr" rid="pntd.0000916-Tarleton1">[11]</xref>.</p>
<p>Several <italic>T. cruzi</italic> vaccine candidates have demonstrated protective effects against challenge in mouse models and offer promise for the future development of a human vaccine <xref ref-type="bibr" rid="pntd.0000916-Dumonteil1">[12]</xref>, . Much attention has focused on DNA vaccines, consisting of one or more antigen-coding plasmids, which may provide sufficient protection without the possibility of reverting back to the infectious form <xref ref-type="bibr" rid="pntd.0000916-Dumonteil1">[12]</xref>.</p>
<p>Understanding the potential economic and health benefits of a <italic>T. cruzi</italic> vaccine could help guide vaccine investment, development, targeting, and implementation, thereby assisting vaccine scientists, manufacturers, policy makers, and other decision makers. It can be helpful to construct economic models early in a vaccine's development, before key decisions about the vaccine are made and while important aspects of the vaccine can still be altered <xref ref-type="bibr" rid="pntd.0000916-Lee1">[14]</xref>. We developed a computer model to evaluate the economic value of a <italic>T. cruzi</italic> vaccine for the control of Chagas disease in Latin America. Different scenarios helped determine the effects of varying various key vaccine characteristics such as vaccine efficacy (to guide development), vaccine cost (to help set future price points), and risk of infection (to identify appropriate target populations).</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Model Structure</title>
<p>We constructed a Markov decision analytic computer simulation model to assess the potential cost-effectiveness of a <italic>T. cruzi</italic> vaccine in Latin America using TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachusetts). The model assumed the societal perspective and evaluated the economic value of vaccination versus no vaccination of a cohort of children &lt;1 year of age to prevent <italic>T. cruzi</italic> infection and Chagas disease. Each cycle length was one year. <xref ref-type="fig" rid="pntd-0000916-g001">Figure 1</xref> illustrates the general model structure, including the following six Markov states of the disease model and an individual's possible transitions between states:</p>
<list list-type="bullet"><list-item>
<p>Susceptible/Well: The individual was healthy and uninfected during this year.</p>
</list-item><list-item>
<p>Acute Phase: The individual was actually infected with <italic>T. cruzi</italic>. Infected individuals only remain in this state for 1 year.</p>
</list-item><list-item>
<p>Indeterminate Phase: The latent phase of disease subsequent to the acute phase. Those who became infected could remain here for 10 years or more before transitioning to a chronic form of Chagas disease, or could have remained in this phase for life.</p>
</list-item><list-item>
<p>Chronic Cardiomyopathy without CHF: Cardiac abnormalities existed, but CHF had not developed. Cases that entered into this state then had an annual probability of progressing to CHF.</p>
</list-item><list-item>
<p>Chronic Cardiomyopathy with CHF: Individual had CHF.</p>
</list-item><list-item>
<p>Death: Death occurred as a result of either Chagas disease (acute or chronic) or other causes unrelated to <italic>T. cruzi</italic> infection.</p>
</list-item></list>
<fig id="pntd-0000916-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.g001</object-id><label>Figure 1</label><caption>
<title>Model Markov states.</title>
<p>* Arrows represent states where Chagas-related death could occur. Non-Chagas-related death could occur during any state.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.g001" xlink:type="simple"/></fig>
<p>All Markov states were mutually exclusive. Individuals entered the model at age 0 and began in the ‘Susceptible/Well’ state (i.e., well with no prior history of infection). Each passing year, the individual either remained in the same state or transitioned to another state. The individual continued in the model until he or she entered the Death state from (1) acute/symptomatic infection, (2) cardiomyopathy with or without CHF, or (3) mortality unrelated to <italic>T. cruzi</italic> infection, where they remained for the remainder of the trial <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref>.</p>
<p><xref ref-type="fig" rid="pntd-0000916-g002">Figure 2a–e</xref> shows the possible paths an individual could have traveled through after entering each Markov state. After entering the ‘Susceptible/Well’ state, an individual had probabilities of becoming infected (symptomatic or asymptomatic infection), dying of unrelated causes, or remaining uninfected. Only symptomatic cases had a probability of seeking <italic>T. cruzi</italic> treatment during the acute phase. Consistent with standard medical operating procedure, developing severe side effects resulted in discontinuation of drug treatment and therefore eliminating any chance the treatment could be successful. Asymptomatic cases did not receive treatment and proceeded directly to the indeterminate (latent) disease phase. The reported time from acute illness to development of chronic cardiac manifestations in the literature ranged from 10 to 30 years; infected individuals in the model therefore had to stay in the indeterminate phase for at least 10 cycles (years) before having an annual probability of developing cardiomyopathy (with or without CHF) <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Punukollu1">[15]</xref>, <xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Hidron1">[17]</xref>. Those who sought a form of treatment for chronic infection once continued to do so throughout the remainder of their life span.</p>
<fig id="pntd-0000916-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.g002</object-id><label>Figure 2</label><caption>
<title>Markov state subtrees.</title>
<p>A) Susceptible/Well B) Acute Phase C) Indeterminate Phase D) Cardiomyopathy with CHF E) Cardiomyopathy without CHF. * Death resulting from Chagas infection ** Death from non-Chagas related causes.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.g002" xlink:type="simple"/></fig>
<p>Each simulation run sent 1,000 individuals through the model 1,000 times each for a total of 1,000,000 individual realizations. For each simulation run, the following equation computed the incremental cost-effectiveness ratio (ICER), or cost per disability-adjusted life year (DALY) avoided, through vaccination:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.e001" xlink:type="simple"/></disp-formula>Quantification of DALY decrements for vaccinating and not vaccinating included the years lost due to disability from Chagas (YLD) as well as the years of life lost as a result of Chagas-related mortality (YLL). Costs included both direct and indirect costs (such as productivity loss) that resulted from becoming a Chagas case. The cost-effectiveness of vaccination for each scenario was evaluated using the GDP per capita of Colombia ($5,048.41), as it represented the approximate average GDP per capita for all of Latin America <xref ref-type="bibr" rid="pntd.0000916-International1">[18]</xref>, <xref ref-type="bibr" rid="pntd.0000916-United1">[19]</xref>. Vaccination was considered highly cost-effective if the ICER value was $5,048.41 per DALY avoided or less. Scenarios that yielded an ICER of $15,145.23 per DALY (3 times the GDP per capita) avoided or less still indicated that vaccination was cost-effective, while ICERs greater than 3 times the GDP per capita indicated that vaccination was not a cost-effective strategy. The cost of vaccinating an individual was calculated by comparing the average cost accrued on the vaccine arm of the model to the average cost accrued on the no vaccine arm over the 1 million trials for each simulation. The cost per avoided congestive heart failure (CHF) case was calculated by dividing the cost difference between the vaccine and no vaccine arm for the entire cohort by the total number of CHF cases avoided on the vaccine arm/branch (compared to the no vaccine branch) for the simulation.</p>
</sec><sec id="s2b">
<title>Data Inputs</title>
<p><xref ref-type="table" rid="pntd-0000916-t001">Table 1</xref> shows the cost, probability, and DALY model input values and their corresponding sources. The probability of an acute case being symptomatic in the model was 1%. Based on a report of treatment-seeking behavior for febrile illness, the probability that a symptomatic individual sought treatment was 34% <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Coura1">[8]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Goldman1">[20]</xref>. For treatment costs, life expectancy, and crude mortality rates, data from Colombia, where Chagas prevalence is high, served as a proxy for Latin America <xref ref-type="bibr" rid="pntd.0000916-United1">[19]</xref>. World Health Organization (WHO) sources provided disability weights for cardiomyopathy with and without CHF as well as crude mortality rates (0–11 mos, 1.65%; 1–4 yrs, 0.32%; 5–9 yrs, 0.15%; 10–14 yrs, 0.18%; 15–19 yrs, 0.55%; 20–24 yrs, 0.97%; 25–29 yrs, 1.08%; 30–34 yrs, 1.02%; 35–39 yrs, 1.02%; 40–44 yrs, 1.12%; 45–49 yrs, 1.58%; 50–54 yrs, 2.11%; 55–59 yrs, 3.12%; 60–64 yrs, 4.99%; 65–69 yrs, 9.07%; 70–74 yrs, 14.66%; 75–79 yrs, 23.85%; 80–84 yrs, 30.62%; 85–89 yrs, 40.46%; 90–94 yrs, 51.70%; 95–99 yrs, 64.50%; 100 yrs and older, 100%) and life expectancies (0–11 mos, 75.5 yrs; 1–4 yrs, 75.8 yrs; 5–9 yrs, 72 yrs; 10–14 yrs, 67.1 yrs; 15–19 yrs, 62.2 yrs; 20–24 yrs, 57.5 yrs; 25–29 yrs, 53.1 yrs; 30–34 yrs, 48.6 yrs; 35–39 yrs, 44.1 yrs; 40–44 yrs, 39.5 yrs; 45–49 yrs, 35 yrs; 50–54 yrs, 30.4 yrs; 55–59 yrs, 26 yrs; 60–64 yrs, 21.8 yrs; 65–69 yrs, 17.8 yrs; 70–74 yrs, 14.3 yrs; 75–79 yrs, 11.4 yrs; 80–84 yrs, 9.2 yrs; 85–89 yrs, 7.1 yrs; 90–94 yrs, 5.2 yrs; 95–99 yrs, 3.6 yrs; 100 yrs and older, 2.5yrs) <xref ref-type="bibr" rid="pntd.0000916-World1">[21]</xref>, <xref ref-type="bibr" rid="pntd.0000916-World2">[22]</xref>.</p>
<table-wrap id="pntd-0000916-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.t001</object-id><label>Table 1</label><caption>
<title>Model inputs.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0000916-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.t001" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Variable</td>
<td align="left" colspan="1" rowspan="1">Baseline Value</td>
<td align="left" colspan="1" rowspan="1">Source</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="3" rowspan="1"><bold>PROBABILITIES</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Benznidazole Cure Rate Acute Phase</td>
<td align="left" colspan="1" rowspan="1">0.65<xref ref-type="table-fn" rid="nt101">a</xref></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Coura2">[26]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Yun1">[28]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Drug Side Effects</td>
<td align="left" colspan="1" rowspan="1">0.05</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Yun1">[28]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mortality Acute Phase</td>
<td align="left" colspan="1" rowspan="1">0.05<xref ref-type="table-fn" rid="nt102">b</xref></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Annual Rate of Progression to Chronic Phase</td>
<td align="left" colspan="1" rowspan="1">0.02</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Punukollu1">[15]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiomyopathy</td>
<td align="left" colspan="1" rowspan="1">0.25<xref ref-type="table-fn" rid="nt103">c</xref></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Seek Treatment if Cardiomyopathy</td>
<td align="left" colspan="1" rowspan="1">0.35</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CHF if Cardiomyopathy</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mortality CHF</td>
<td align="left" colspan="1" rowspan="1">0.30</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mortality No CHF</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1"><bold>DISABILITY WEIGHTS</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiomyopathy CHF</td>
<td align="left" colspan="1" rowspan="1">0.27</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-World2">[22]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiomyopathy No CHF</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-World2">[22]</xref></td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1"><bold>COSTS (US$)</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Palliative Care Only CHF<xref ref-type="table-fn" rid="nt104">d</xref></td>
<td align="left" colspan="1" rowspan="1">42</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Palliative Care Only No CHF</td>
<td align="left" colspan="1" rowspan="1">23</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Basic Care CHF<xref ref-type="table-fn" rid="nt105">e</xref></td>
<td align="left" colspan="1" rowspan="1">61</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Basic Care No CHF<xref ref-type="table-fn" rid="nt106">f</xref></td>
<td align="left" colspan="1" rowspan="1">55</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Intermediate Care CHF<xref ref-type="table-fn" rid="nt107">g</xref></td>
<td align="left" colspan="1" rowspan="1">310</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Intermediate Care No CHF</td>
<td align="left" colspan="1" rowspan="1">224</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Specialized Care CHF<xref ref-type="table-fn" rid="nt108">h</xref></td>
<td align="left" colspan="1" rowspan="1">9,530</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Specialized Care No CHF</td>
<td align="left" colspan="1" rowspan="1">4,360</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-CastilloRiquelme1">[16]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Indeterminate Phase</td>
<td align="left" colspan="1" rowspan="1">105</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref></td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p>Uniform distribution with a lower limit of 0.5 and an upper limit of 0.8.</p></fn><fn id="nt102"><label>b</label><p>Triangular distribution with a lower limit of 0.01 and an upper limit of 0.1.</p></fn><fn id="nt103"><label>c</label><p>Uniform distribution with a lower limit of 0.2 and an upper limit of 0.3.</p></fn><fn id="nt104"><label>d</label><p>Refers to cases only seeking care to minimize their symptoms, not to prevent or delay progression of disease.</p></fn><fn id="nt105"><label>e</label><p>Consisted of 3 general practitioner visits and 0.58 days in the hospital.</p></fn><fn id="nt106"><label>f</label><p>Consisted of 5.53 general practitioner visits and 0.25 days in the hospital.</p></fn><fn id="nt107"><label>g</label><p>Included outpatient visits, diagnostics, medicine, and hospitalization costs.</p></fn><fn id="nt108"><label>h</label><p>Included outpatient care, hospitalization, and hospital procedures such as electrocardiography, x-rays, and surgery.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c">
<title>Sensitivity Analyses</title>
<p>Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (ranging from a low of $0.50 up to the cost at which the vaccine was no longer cost-effective), vaccine efficacy in preventing infection (range: 25% to 75%), the cost of acute-phase drug treatment (range: $10–$150 to account for variations in acute-phase treatment regimens), and risk of infection (range: 1%–20%) <xref ref-type="bibr" rid="pntd.0000916-Wolfson1">[23]</xref>. As many studies report a cost associated with routine surveillance (i.e., clinic visits, radiographs, electrocardiograms, and laboratory tests) during the indeterminate phase, additional sensitivity analyses varied the probability that an individual accrued a cost while in this phase from 25%–75% <xref ref-type="bibr" rid="pntd.0000916-Wilson1">[6]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Basombrio1">[24]</xref>. Probabilistic sensitivity analyses determined the effects of simultaneously varying parameter values across their respective ranges.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Overall Impact</title>
<p>Results suggest that a <italic>T. cruzi</italic> vaccine would be cost-effective across a wide range of vaccine prices and efficacies and <italic>T. cruzi</italic> infection risks. In fact, in many cases, a <italic>T. cruzi</italic> vaccine could actually save costs (i.e., that would be associated with treating the disease) in addition to providing health benefits. Vaccination remained cost-effective even up to a vaccine price of $75 when infection risk was 5% and vaccine efficacy was greater than 50% and up to a vaccine price of $200 when the vaccine efficacy was 75% or greater.</p>
</sec><sec id="s3b">
<title>Cost-Effectiveness</title>
<p>The majority of our modeled scenarios demonstrated vaccination to be very cost-effective, and in many cases highly cost-effective, especially with lower vaccine price points, compared to no vaccination. <xref ref-type="table" rid="pntd-0000916-t002">Table 2</xref> indicates the incremental cost-effectiveness ratio (ICER) of Chagas vaccination at various vaccine costs, infection risks and vaccine efficacy rates. When the total vaccine cost was less than $5, vaccination was highly cost-effective across all scenarios of infection risk (1%, 5%, 10% and 20%) and vaccine efficacy (25%, 50%, and 75%). Increasing the vaccine price to $10 alters the vaccine strategy to cost-effective across all scenarios, and finally when the vaccine cost is $20 and vaccine efficacy is 25%, some scenarios become cost-ineffective. However, when the vaccine efficacy is greater than 50%, vaccination remains cost-effective until a $50 vaccine price point at 1% infection rate, a $75 vaccine price point at 5% infection rate, and a $100 vaccine price point at 10% infection rate. Vaccination remains cost-effective at a $200 price point when the efficacy is greater than 50% and infection risk is 20%. The model was fairly robust and displayed minimal sensitivity to variation in treatment costs for acute infection and the probability of an indeterminate phase-associated cost.</p>
<table-wrap id="pntd-0000916-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.t002</object-id><label>Table 2</label><caption>
<title>The incremental cost-effectiveness ratio (ICER) of Chagas vaccination in US dollars.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0000916-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.t002" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="4" rowspan="1">Risk of <italic>T. cruzi</italic> Infection</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>Vaccine Efficacy</italic></td>
<td align="left" colspan="1" rowspan="1">1%</td>
<td align="left" colspan="1" rowspan="1">5%</td>
<td align="left" colspan="1" rowspan="1">10%</td>
<td align="left" colspan="1" rowspan="1">20%</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $0.50</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $1</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $5</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>1,335</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $10</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>5,485</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>2,526</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>1,331</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>7,178</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>800</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $20</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>10,111</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1,208</bold></td>
<td align="left" colspan="1" rowspan="1">Don't Vaccinate</td>
<td align="left" colspan="1" rowspan="1"><bold>1,143</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>7,541</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>205</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>5,629</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $30</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">Don't Vaccinate</td>
<td align="left" colspan="1" rowspan="1"><bold>5,358</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1,520</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>6,967</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>10,849</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>746</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>8,987</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $50</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">Don't Vaccinate</td>
<td align="left" colspan="1" rowspan="1">21,787</td>
<td align="left" colspan="1" rowspan="1">30,651</td>
<td align="left" colspan="1" rowspan="1"><bold>5,031</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">23,012</td>
<td align="left" colspan="1" rowspan="1"><bold>3,201</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1,007</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>898</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">21,234</td>
<td align="left" colspan="1" rowspan="1"><bold>1,319</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>Vaccinate</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $75</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">221,657</td>
<td align="left" colspan="1" rowspan="1">35,065</td>
<td align="left" colspan="1" rowspan="1"><bold>14,051</bold></td>
<td align="left" colspan="1" rowspan="1">17,806</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">26,492</td>
<td align="left" colspan="1" rowspan="1"><bold>14,614</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>4,097</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>5,316</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">55,203</td>
<td align="left" colspan="1" rowspan="1"><bold>6,872</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>713</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>176</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $100</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">Don't Vaccinate</td>
<td align="left" colspan="1" rowspan="1">45,307</td>
<td align="left" colspan="1" rowspan="1">46,693</td>
<td align="left" colspan="1" rowspan="1">34,017</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">450,040</td>
<td align="left" colspan="1" rowspan="1">36,600</td>
<td align="left" colspan="1" rowspan="1"><bold>8,757</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>5,263</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">20,639</td>
<td align="left" colspan="1" rowspan="1"><bold>3,091</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>4,452</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>3,875</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $200</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">122,109</td>
<td align="left" colspan="1" rowspan="1">71,062</td>
<td align="left" colspan="1" rowspan="1">26,972</td>
<td align="left" colspan="1" rowspan="1">36,640</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">Don't Vaccinate</td>
<td align="left" colspan="1" rowspan="1">58,412</td>
<td align="left" colspan="1" rowspan="1">50,385</td>
<td align="left" colspan="1" rowspan="1"><bold>8,743</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">46,471</td>
<td align="left" colspan="1" rowspan="1"><bold>12,536</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>8,247</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>5,485</bold></td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt109"><label/><p>Bold numbers indicate a cost-effective strategy.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c">
<title>Budget Impact Analysis</title>
<p><xref ref-type="table" rid="pntd-0000916-t003">Table 3</xref> shows that vaccinating an individual can actually be cost savings under many explored circumstances. Negative values in the table indicate that vaccinating an individual resulted in cost savings (i.e., there was actually net monetary gain from vaccinating an individual). For example, when a $1 vaccine was only 25% efficacious and the risk of infection was 1%, vaccinating an individual would on average save $1.52. At infection rates as low as 1%, vaccination was cost-saving up to a $5 vaccine price point as long as the vaccine remained at least 50% efficacious, with savings overall ranging from −$0.07 to −$81.26 per vaccinated individual. Vaccination remained cost-saving for all scenarios under a $10 vaccine price point, when the risk of infection was 5% or greater, averting the most cost (−$81) per vaccinee when vaccine price was $1, efficacy was 75%, and infection risk was 20%. Administering vaccine only resulted in net cost ($2.44–$7.26) at low infection risk (1%) and vaccine price point of $10 for the entire range of evaluated vaccine efficacies. The cost benefit persisted when the vaccine efficacy was 50% at vaccine costs of $20–$30 when infection risk was greater of equal to 10%. When the vaccine was 75% efficacious, a cost savings exists for vaccine prices of ≤$50. For a vaccine cost of $200, the incremental cost of vaccinating an individual ranged from $111.03 (20% infection rate, 75% vaccine efficacy) to $197.36 (1% infection rate, 25% vaccine efficacy).</p>
<table-wrap id="pntd-0000916-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.t003</object-id><label>Table 3</label><caption>
<title>The incremental cost of vaccinating an individual ($US).</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0000916-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.t003" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="4" rowspan="1">Risk of <italic>T. cruzi</italic> Infection</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>Vaccine Efficacy</italic></td>
<td align="left" colspan="1" rowspan="1">1%</td>
<td align="left" colspan="1" rowspan="1">5%</td>
<td align="left" colspan="1" rowspan="1">10%</td>
<td align="left" colspan="1" rowspan="1">20%</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $1</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−1.52</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−9.26</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−15.61</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−18.49</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−4.29</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−21.92</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−31.24</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−50.02</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−7.10</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−38.07</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−55.04</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−81.26</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $5</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">2.21</td>
<td align="left" colspan="1" rowspan="1"><bold>−5.99</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−10.78</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−15.65</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−0.07</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−16.47</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−33.73</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−40.88</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−4.08</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−31.31</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−54.09</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−78.27</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $10</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">7.26</td>
<td align="left" colspan="1" rowspan="1"><bold>−0.94</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−7.21</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−10.45</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">4.54</td>
<td align="left" colspan="1" rowspan="1"><bold>−12.97</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−28.66</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−36.90</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">2.44</td>
<td align="left" colspan="1" rowspan="1"><bold>−26.71</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−51.38</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−76.66</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $20</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">17.53</td>
<td align="left" colspan="1" rowspan="1">10.28</td>
<td align="left" colspan="1" rowspan="1">3.73</td>
<td align="left" colspan="1" rowspan="1">1.98</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">15.47</td>
<td align="left" colspan="1" rowspan="1">1.18</td>
<td align="left" colspan="1" rowspan="1"><bold>−13.28</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−22.20</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">13.02</td>
<td align="left" colspan="1" rowspan="1"><bold>−11.52</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−33.08</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−54.50</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $30</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">27.57</td>
<td align="left" colspan="1" rowspan="1">21.37</td>
<td align="left" colspan="1" rowspan="1">13.99</td>
<td align="left" colspan="1" rowspan="1">11.96</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">25.80</td>
<td align="left" colspan="1" rowspan="1">10.54</td>
<td align="left" colspan="1" rowspan="1"><bold>−3.23</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−10.45</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">23.35</td>
<td align="left" colspan="1" rowspan="1"><bold>−2.58</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−20.68</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−48.44</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $50</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">47.52</td>
<td align="left" colspan="1" rowspan="1">40.78</td>
<td align="left" colspan="1" rowspan="1">36.18</td>
<td align="left" colspan="1" rowspan="1">7.96</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">45.10</td>
<td align="left" colspan="1" rowspan="1">28.77</td>
<td align="left" colspan="1" rowspan="1">17.91</td>
<td align="left" colspan="1" rowspan="1">33.27</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">42.54</td>
<td align="left" colspan="1" rowspan="1">17.79</td>
<td align="left" colspan="1" rowspan="1"><bold>−1.28</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−24.04</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $75</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">72.91</td>
<td align="left" colspan="1" rowspan="1">64.70</td>
<td align="left" colspan="1" rowspan="1">60.51</td>
<td align="left" colspan="1" rowspan="1">55.47</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">70.64</td>
<td align="left" colspan="1" rowspan="1">54.00</td>
<td align="left" colspan="1" rowspan="1">43.79</td>
<td align="left" colspan="1" rowspan="1">31.81</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">68.30</td>
<td align="left" colspan="1" rowspan="1">43.62</td>
<td align="left" colspan="1" rowspan="1">20.78</td>
<td align="left" colspan="1" rowspan="1">3.45</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $100</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">97.50</td>
<td align="left" colspan="1" rowspan="1">90.26</td>
<td align="left" colspan="1" rowspan="1">84.13</td>
<td align="left" colspan="1" rowspan="1">81.40</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">95.58</td>
<td align="left" colspan="1" rowspan="1">80.67</td>
<td align="left" colspan="1" rowspan="1">68.17</td>
<td align="left" colspan="1" rowspan="1">60.08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">93.37</td>
<td align="left" colspan="1" rowspan="1">67.85</td>
<td align="left" colspan="1" rowspan="1">45.09</td>
<td align="left" colspan="1" rowspan="1">28.40</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $200</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">197.36</td>
<td align="left" colspan="1" rowspan="1">190.82</td>
<td align="left" colspan="1" rowspan="1">184.64</td>
<td align="left" colspan="1" rowspan="1">181.15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">194.71</td>
<td align="left" colspan="1" rowspan="1">180.03</td>
<td align="left" colspan="1" rowspan="1">165.09</td>
<td align="left" colspan="1" rowspan="1">154.43</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">193.28</td>
<td align="left" colspan="1" rowspan="1">166.69</td>
<td align="left" colspan="1" rowspan="1">148.32</td>
<td align="left" colspan="1" rowspan="1">111.03</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt110"><label/><p>Incremental costs refer to the difference between the cost of vaccinating and the cost of not vaccinating. Negative values indicate net cost savings with vaccination; positive values indicate net costs with vaccination.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d">
<title>Cost per CHF Case Averted</title>
<p><xref ref-type="table" rid="pntd-0000916-t004">Table 4</xref> displays the cost per CHF case averted by vaccination. As can be seen, since the vaccine in most cases is cost savings, there is actually net savings per CHF case averted. The greatest cost savings per CHF case avoided were seen at the lowest vaccine cost ($1) and the lowest infection rates (1%). Under every scenario with a vaccine cost of ≤$10 (regardless of indeterminate phase-cost association or vaccine efficacy) and infection rates of 5% or above, the cost per CHF case averted was negative, indicating a cost savings per case avoided through vaccination. When infection rates were 1% and vaccine cost increased to $10, the cost per avoided CHF case was $50, 883 at 75% vaccine efficacy. At lower efficacies (50% and 25%), cost per CHF case averted increased to $126,009 and $660,350, respectively. At a vaccine price point of $5, vaccinating to prevent a case of CHF ranged from costing over $100,000 to saving over $100,000, depending on vaccine efficacy.</p>
<table-wrap id="pntd-0000916-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000916.t004</object-id><label>Table 4</label><caption>
<title>The cost per avoided case of congestive heart failure (CHF) ($US).</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0000916-t004-4" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0000916.t004" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="4" rowspan="1">Risk of <italic>T. cruzi</italic> Infection</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>Vaccine Efficacy</italic></td>
<td align="left" colspan="1" rowspan="1">1%</td>
<td align="left" colspan="1" rowspan="1">5%</td>
<td align="left" colspan="1" rowspan="1">10%</td>
<td align="left" colspan="1" rowspan="1">20%</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $1</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−108,779</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−132,304</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−130,069</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−81,435</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−195,117</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−171,231</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−135,221</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−100,237</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−154,287</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−186,595</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−152,040</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−115,263</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $5</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">234,280</td>
<td align="left" colspan="1" rowspan="1"><bold>−117,542</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−91,333</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−66,319</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−2,743</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−145,784</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−156,898</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−96,642</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1"><bold>−110,259</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−166,543</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−146,197</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−110,397</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $10</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">660,350</td>
<td align="left" colspan="1" rowspan="1"><bold>−19,480</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−63,273</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−41,302</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">126,009</td>
<td align="left" colspan="1" rowspan="1"><bold>−102,932</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−118,409</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−78,352</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">50,883</td>
<td align="left" colspan="1" rowspan="1"><bold>−157,108</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−138,875</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−108,278</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $20</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">1,252,352</td>
<td align="left" colspan="1" rowspan="1">151,155</td>
<td align="left" colspan="1" rowspan="1">31,876</td>
<td align="left" colspan="1" rowspan="1">8,486</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">967,156</td>
<td align="left" colspan="1" rowspan="1">10,071</td>
<td align="left" colspan="1" rowspan="1"><bold>−57,757</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−44,047</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">419,868</td>
<td align="left" colspan="1" rowspan="1"><bold>−61,587</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−93,459</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−72,470</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $30</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">2,121,101</td>
<td align="left" colspan="1" rowspan="1">403,277</td>
<td align="left" colspan="1" rowspan="1">123,817</td>
<td align="left" colspan="1" rowspan="1">41,973</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">1,032,053</td>
<td align="left" colspan="1" rowspan="1">83,686</td>
<td align="left" colspan="1" rowspan="1"><bold>−13,118</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−20,900</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">631,111</td>
<td align="left" colspan="1" rowspan="1"><bold>−13,236</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−57,275</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−69,105</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $50</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">4,751,919</td>
<td align="left" colspan="1" rowspan="1">608,643</td>
<td align="left" colspan="1" rowspan="1">282,693</td>
<td align="left" colspan="1" rowspan="1">18,599</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">1,503,296</td>
<td align="left" colspan="1" rowspan="1">241,724</td>
<td align="left" colspan="1" rowspan="1">74,020</td>
<td align="left" colspan="1" rowspan="1">149,209</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">1,519,255</td>
<td align="left" colspan="1" rowspan="1">102,249</td>
<td align="left" colspan="1" rowspan="1"><bold>−3,714</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>−33,620</bold></td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $75</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">4,860,652</td>
<td align="left" colspan="1" rowspan="1">1,043,606</td>
<td align="left" colspan="1" rowspan="1">521,635</td>
<td align="left" colspan="1" rowspan="1">224,576</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">3,360,131</td>
<td align="left" colspan="1" rowspan="1">409,098</td>
<td align="left" colspan="1" rowspan="1">207,532</td>
<td align="left" colspan="1" rowspan="1">58,802</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">1,751,278</td>
<td align="left" colspan="1" rowspan="1">241,000</td>
<td align="left" colspan="1" rowspan="1">55,279</td>
<td align="left" colspan="1" rowspan="1">4,612</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $100</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">8,863,707</td>
<td align="left" colspan="1" rowspan="1">1,920,387</td>
<td align="left" colspan="1" rowspan="1">657,249</td>
<td align="left" colspan="1" rowspan="1">347,864</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">3,540,061</td>
<td align="left" colspan="1" rowspan="1">783,224</td>
<td align="left" colspan="1" rowspan="1">333,905</td>
<td align="left" colspan="1" rowspan="1">129,760</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">2,593,484</td>
<td align="left" colspan="1" rowspan="1">387,727</td>
<td align="left" colspan="1" rowspan="1">122,528</td>
<td align="left" colspan="1" rowspan="1">40,520</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1"><bold>Vaccine Cost = $200</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>25%</italic></td>
<td align="left" colspan="1" rowspan="1">14,097,245</td>
<td align="left" colspan="1" rowspan="1">2,981,599</td>
<td align="left" colspan="1" rowspan="1">1,538,697</td>
<td align="left" colspan="1" rowspan="1">846,508</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>50%</italic></td>
<td align="left" colspan="1" rowspan="1">8,465,638</td>
<td align="left" colspan="1" rowspan="1">1,636,654</td>
<td align="left" colspan="1" rowspan="1">657,726</td>
<td align="left" colspan="1" rowspan="1">307,633</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"><italic>75%</italic></td>
<td align="left" colspan="1" rowspan="1">5,368,789</td>
<td align="left" colspan="1" rowspan="1">963,519</td>
<td align="left" colspan="1" rowspan="1">429,911</td>
<td align="left" colspan="1" rowspan="1">170,284</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt111"><label/><p>Negative values indicate net cost savings with vaccination; positive values indicate net costs with vaccination.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4">
<title>Discussion</title>
<p>Our results support further development and future implementation of a <italic>T. cruzi</italic> vaccine and have several implications for vaccine policy makers, developers, and manufacturers. A <italic>T. cruzi</italic> vaccine could not only decrease infection burden, but also severe cardiac disease in Latin America. Our results suggest that vaccination would be highly cost-effective (and in some cases, economically dominant) over a wide range of infection rates, treatment-seeking behaviors, and vaccine costs. Such findings imply that vaccination may be beneficial even in areas with low risk of infection or in endemic areas that are improving (i.e., decreasing infection risk) over time. Demonstrating that the vaccine could provide net cost savings even at relatively higher vaccine price points (such as $50) could encourage manufacturers to pursue development and eventual commercialization of the vaccine. Additionally, as our analysis suggests that the target efficacy window for a vaccine can be fairly wide; scientists do not necessarily have to design the near “perfect” vaccine that confers protection close to 100% in order to establish economic value. Even vaccines that offer lower levels of protection can be valuable, especially at lower vaccine prices. Moreover, our study suggests that a <italic>T. cruzi</italic> vaccine may actually “pay for itself”: even a relatively higher priced vaccine of $50 can generate net cost savings for a purchaser (e.g., a country's ministry of health).</p>
<p>As our results demonstrate, vaccine price helps drive the net costs and cost-effectiveness of a <italic>T. cruzi</italic> vaccine. A vaccine that costs $30 or less is cost-effective under most explored conditions. However, a vaccine that costs $100 or more is cost-effective under a much more limited set of circumstances. Our results may help decision-makers map out the appropriate prices for a given situation.</p>
<p>A <italic>T. cruzi</italic> vaccine could affect the epidemiology of cardiac disease in endemic populations and countries. As management of cardiomyopathy and CHF are associated with intensive and costly medical care, preventing such outcomes would likely alleviate a substantial burden on the healthcare system. A study conducted by Mendez <italic>et al.</italic> reported that 20% of all cardiovascular disease patients seen in a particular Brazilian health institution had Chagas-related cardiomyopathy, and suggests that unresolved Chagas infection accounts for nearly 30% of all CHF cases in Brazil <xref ref-type="bibr" rid="pntd.0000916-Mendez1">[25]</xref>. Additional literature suggests that a similar proportion of CHF cases (20%) in Colombia result from Chagas disease <xref ref-type="bibr" rid="pntd.0000916-CubillosGarzon1">[2]</xref>. Chagas disease may play an even larger role in causing cardiac disease in other parts of Latin America.</p>
<p>Limitations of current alternatives have spurred efforts to develop a <italic>T. cruzi</italic> vaccine. Although drugs exist for the treatment of Chagas disease, they have many complications and are associated with long treatment regimens and low cure rates when administered after the acute disease phase <xref ref-type="bibr" rid="pntd.0000916-Coura2">[26]</xref>. DNA vaccines have recently shown promise against several protozoan parasitic diseases, such as malaria, leishmaniasis, and Chagas disease, as they have proven to be safe and elicit a complete immune response. Furthermore, their thermo-stability and affordability may make them highly practical for use in resource poor settings where these diseases are endemic. While this technology has yet to yield an efficacious Chagas vaccine for the human population, the development and licensure of DNA vaccines against West Nile and infectious hematopoietic necrosis viruses in animals give promise for a future human vaccine <xref ref-type="bibr" rid="pntd.0000916-Dumonteil1">[12]</xref>. Certainly bringing a <italic>T. cruzi</italic> vaccine to market would involve surmounting a variety of scientific hurdles, but our study suggests that surmounting such obstacles could be very worthwhile <xref ref-type="bibr" rid="pntd.0000916-Dumonteil1">[12]</xref>.</p>
<p>In developing our model, we attempted to remain conservative about the benefits of a vaccine. The actual costs of diagnosing and treating CHF may be much higher than the numbers used. In addition, CHF could have substantial repercussions on an individual's life which were not captured by the model. The model assumed that individuals were otherwise healthy, but the addition of co-morbidities or co-infection with other pathogens such as the human immunodeficiency virus (HIV) could worsen outcomes for individuals infected with <italic>T. cruzi</italic>. Moreover, our model did not consider how the vaccine may reduce the transmission of <italic>T. cruzi</italic> by reducing available human hosts. The risk of infection may be higher than reported, as many cases go undiagnosed. Our range of infection probabilities came from Global Health Statistics reports but may not include regions and populations with higher risk <xref ref-type="bibr" rid="pntd.0000916-CubillosGarzon1">[2]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Mendez1">[25]</xref>, <xref ref-type="bibr" rid="pntd.0000916-Murray1">[27]</xref>. Some studies have reported the direct progression from acute to chronic disease as well as sudden death due to cardiac complications during the indeterminate phase; however, these possibilities were difficult to measure accurately and therefore not incorporated into the model parameters <xref ref-type="bibr" rid="pntd.0000916-Rassi1">[5]</xref>.</p>
<sec id="s4a">
<title>Limitations</title>
<p>All computer models are simplifications of real world scenarios and therefore cannot capture all possible outcomes of Chagas disease or the efficacy of concurrent existing regional control methods. Our model focuses on the individual rather than a population and therefore, does not explicitly represent herd immunity. However, increasing herd immunity could decrease Chagas risk, and our study demonstrates how changes in Chagas disease risk would affect the vaccine's economic value. Additionally, this model cannot account for the variation in high risk exposure resulting from factors such as environmental conditions or individual behaviors across Latin America. Although model assumptions and data inputs were drawn from an extensive review of the literature, sources may vary in quality and input values may not hold under all conditions.</p>
</sec><sec id="s4b">
<title>Conclusion</title>
<p>Our model suggests that introducing a <italic>T. cruzi</italic> vaccine to Latin America would provide economic value. Such a vaccine could be highly cost-effective and many cases could be economically dominant, providing both cost savings and health benefits. Even a vaccine with fairly low efficacy (25%) can provide cost savings. Moreover, a vaccine could be cost-effective even at relatively low infection risks (1%). Such findings support continued efforts to develop a human vaccine against <italic>T. cruzi</italic> to help reduce the significant burden of Chagas disease.</p>
</sec></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pntd.0000916-SosaEstani1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sosa-Estani</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Viotti</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Segura</surname><given-names>EL</given-names></name>
</person-group>             <year>2009</year>             <article-title>Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina.</article-title>             <source>Mem Inst Oswaldo Cruz</source>             <volume>104</volume>             <supplement>Suppl 1</supplement>             <fpage>167</fpage>             <lpage>180</lpage>          </element-citation></ref>
<ref id="pntd.0000916-CubillosGarzon1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cubillos-Garzon</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Casas</surname><given-names>JP</given-names></name>
<name name-style="western"><surname>Morillo</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Bautista</surname><given-names>LE</given-names></name>
</person-group>             <year>2004</year>             <article-title>Congestive heart failure in Latin America: the next epidemic.</article-title>             <source>Am Heart J</source>             <volume>147</volume>             <fpage>412</fpage>             <lpage>417</lpage>          </element-citation></ref>
<ref id="pntd.0000916-MarinNeto1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Marin Neto</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Simoes</surname><given-names>MV</given-names></name>
<name name-style="western"><surname>Sarabanda</surname><given-names>AV</given-names></name>
</person-group>             <year>1999</year>             <article-title>Chagas' heart disease.</article-title>             <source>Arq Bras Cardiol</source>             <volume>72</volume>             <fpage>247</fpage>             <lpage>280</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Wanderley1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wanderley</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Correa</surname><given-names>FM</given-names></name>
</person-group>             <year>1995</year>             <article-title>Epidemiology of Chagas' heart disease.</article-title>             <source>Sao Paulo Med J</source>             <volume>113</volume>             <fpage>742</fpage>             <lpage>749</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Rassi1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rassi</surname><given-names>A</given-names><suffix>Jr</suffix></name>
<name name-style="western"><surname>Rassi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Marin-Neto</surname><given-names>JA</given-names></name>
</person-group>             <year>2010</year>             <article-title>Chagas disease.</article-title>             <source>Lancet</source>             <volume>375</volume>             <fpage>1388</fpage>             <lpage>1402</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Wilson1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wilson</surname><given-names>LS</given-names></name>
<name name-style="western"><surname>Strosberg</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Barrio</surname><given-names>K</given-names></name>
</person-group>             <year>2005</year>             <article-title>Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models.</article-title>             <source>Am J Trop Med Hyg</source>             <volume>73</volume>             <fpage>901</fpage>             <lpage>910</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Urbina1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Urbina</surname><given-names>JA</given-names></name>
</person-group>             <year>2009</year>             <article-title>New advances in the management of a long-neglected disease.</article-title>             <source>Clin Infect Dis</source>             <volume>49</volume>             <fpage>1685</fpage>             <lpage>1687</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Coura1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Coura</surname><given-names>JR</given-names></name>
</person-group>             <year>2007</year>             <article-title>Chagas disease: what is known and what is needed–a background article.</article-title>             <source>Mem Inst Oswaldo Cruz</source>             <volume>102</volume>             <supplement>Suppl 1</supplement>             <fpage>113</fpage>             <lpage>122</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Cancado1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cancado</surname><given-names>JR</given-names></name>
</person-group>             <year>2002</year>             <article-title>Long term evaluation of etiological treatment of chagas disease with benznidazole.</article-title>             <source>Rev Inst Med Trop Sao Paulo</source>             <volume>44</volume>             <fpage>29</fpage>             <lpage>37</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Guhl1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Guhl</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Vallejo</surname><given-names>GA</given-names></name>
</person-group>             <year>1999</year>             <article-title>Interruption of Chagas disease transmission in the Andean countries: Colombia.</article-title>             <source>Mem Inst Oswaldo Cruz</source>             <volume>94</volume>             <supplement>Suppl 1</supplement>             <fpage>413</fpage>             <lpage>415</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Tarleton1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tarleton</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Reithinger</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Urbina</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Kitron</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Gurtler</surname><given-names>RE</given-names></name>
</person-group>             <year>2007</year>             <article-title>The challenges of Chagas Disease– grim outlook or glimmer of hope.</article-title>             <source>PLoS Med</source>             <volume>4</volume>             <fpage>e332</fpage>          </element-citation></ref>
<ref id="pntd.0000916-Dumonteil1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dumonteil</surname><given-names>E</given-names></name>
</person-group>             <year>2007</year>             <article-title>DNA Vaccines against Protozoan Parasites: Advances and Challenges.</article-title>             <source>J Biomed Biotechnol</source>             <volume>2007</volume>             <fpage>90520</fpage>          </element-citation></ref>
<ref id="pntd.0000916-Giddings1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Giddings</surname><given-names>OK</given-names></name>
<name name-style="western"><surname>Eickhoff</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Sullivan</surname><given-names>NL</given-names></name>
<name name-style="western"><surname>Hoft</surname><given-names>DF</given-names></name>
</person-group>             <year>2010</year>             <article-title>Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.</article-title>             <source>Infect Immun</source>             <volume>78</volume>             <fpage>1333</fpage>             <lpage>1338</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Lee1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lee</surname><given-names>BY</given-names></name>
<name name-style="western"><surname>Burke</surname><given-names>DS</given-names></name>
</person-group>             <year>2010</year>             <article-title>Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles.</article-title>             <source>Vaccine</source>             <volume>28</volume>             <fpage>2806</fpage>             <lpage>2809</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Punukollu1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Punukollu</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Gowda</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>IA</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>VS</given-names></name>
<name name-style="western"><surname>Vasavada</surname><given-names>BC</given-names></name>
</person-group>             <year>2007</year>             <article-title>Clinical aspects of the Chagas' heart disease.</article-title>             <source>Int J Cardiol</source>             <volume>115</volume>             <fpage>279</fpage>             <lpage>283</lpage>          </element-citation></ref>
<ref id="pntd.0000916-CastilloRiquelme1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Castillo-Riquelme</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Guhl</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Turriago</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Pinto</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Rosas</surname><given-names>F</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>The costs of preventing and treating chagas disease in Colombia.</article-title>             <source>PLoS Negl Trop Dis</source>             <volume>2</volume>             <fpage>e336</fpage>          </element-citation></ref>
<ref id="pntd.0000916-Hidron1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hidron</surname><given-names>AI</given-names></name>
<name name-style="western"><surname>Gilman</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Justiniano</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Blackstock</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Lafuente</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2010</year>             <article-title>Chagas cardiomyopathy in the context of the chronic disease transition.</article-title>             <source>PLoS Negl Trop Dis</source>             <volume>4</volume>             <fpage>e688</fpage>          </element-citation></ref>
<ref id="pntd.0000916-International1"><label>18</label><element-citation publication-type="other" xlink:type="simple">             <collab xlink:type="simple">International Monetary Fund</collab>             <year>2010</year>             <source>World Economic and Financial Surveys</source>             <publisher-name>World Economic Outlook Database</publisher-name>          </element-citation></ref>
<ref id="pntd.0000916-United1"><label>19</label><element-citation publication-type="other" xlink:type="simple">             <collab xlink:type="simple">United Nations Childrens Fund (UNICEF)</collab>             <year>2008</year>             <source>UNICEF – Colombia – Statistics</source>          </element-citation></ref>
<ref id="pntd.0000916-Goldman1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Goldman</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Heuveline</surname><given-names>P</given-names></name>
</person-group>             <year>2000</year>             <article-title>Health-seeking behaviour for child illness in Guatemala.</article-title>             <source>Trop Med Int Health</source>             <volume>5</volume>             <fpage>145</fpage>             <lpage>155</lpage>          </element-citation></ref>
<ref id="pntd.0000916-World1"><label>21</label><element-citation publication-type="other" xlink:type="simple">             <collab xlink:type="simple">World Health Organization: Global Health Observatory</collab>             <year>2008</year>             <source>Colombia</source>          </element-citation></ref>
<ref id="pntd.0000916-World2"><label>22</label><element-citation publication-type="other" xlink:type="simple">             <collab xlink:type="simple">World Health Organization</collab>             <year>2004</year>             <source>Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions</source>             <publisher-loc>Geneva</publisher-loc>          </element-citation></ref>
<ref id="pntd.0000916-Wolfson1"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wolfson</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Gasse</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Lee-Martin</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Lydon</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Magan</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006–2015.</article-title>             <source>Bulletin of the World Health Organization</source>             <volume>86</volume>             <fpage>27</fpage>             <lpage>39</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Basombrio1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Basombrio</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Schofield</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Rojas</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>del Rey</surname><given-names>EC</given-names></name>
</person-group>             <year>1998</year>             <article-title>A cost-benefit analysis of Chagas disease control in north-western Argentina.</article-title>             <source>Trans R Soc Trop Med Hyg</source>             <volume>92</volume>             <fpage>137</fpage>             <lpage>143</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Mendez1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mendez</surname><given-names>GF</given-names></name>
<name name-style="western"><surname>Cowie</surname><given-names>MR</given-names></name>
</person-group>             <year>2001</year>             <article-title>The epidemiological features of heart failure in developing countries: a review of the literature.</article-title>             <source>Int J Cardiol</source>             <volume>80</volume>             <fpage>213</fpage>             <lpage>219</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Coura2"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Coura</surname><given-names>JR</given-names></name>
</person-group>             <year>2009</year>             <article-title>Present situation and new strategies for Chagas disease chemotherapy: a proposal.</article-title>             <source>Mem Inst Oswaldo Cruz</source>             <volume>104</volume>             <fpage>549</fpage>             <lpage>554</lpage>          </element-citation></ref>
<ref id="pntd.0000916-Murray1"><label>27</label><element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Murray</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name>
</person-group>             <year>1996</year>             <source>Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions (The Global Burden of Disease and Injury)</source>             <publisher-loc>Cambridge, Mass</publisher-loc>             <publisher-name>Harvard School of Public Health on behalf of the World Health Organization and the World Bank : Distributed by Harvard University Press</publisher-name>          </element-citation></ref>
<ref id="pntd.0000916-Yun1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yun</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Lima</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Ellman</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Chambi</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Castillo</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres.</article-title>             <source>PLoS Negl Trop Dis</source>             <volume>3</volume>             <fpage>e488</fpage>          </element-citation></ref>
</ref-list>

</back>
</article>